2.35
price down icon2.08%   -0.05
after-market 시간 외 거래: 2.53 0.18 +7.66%
loading
전일 마감가:
$2.40
열려 있는:
$2.32
하루 거래량:
240.19K
Relative Volume:
0.64
시가총액:
$45.80M
수익:
-
순이익/손실:
$-40.94M
주가수익비율:
-0.612
EPS:
-3.84
순현금흐름:
$-22.97M
1주 성능:
+18.69%
1개월 성능:
+59.86%
6개월 성능:
-64.98%
1년 성능:
-60.83%
1일 변동 폭
Value
$2.275
$2.35
1주일 범위
Value
$1.97
$2.58
52주 변동 폭
Value
$1.11
$17.88

Annovis Bio Inc Stock (ANVS) Company Profile

Name
명칭
Annovis Bio Inc
Name
전화
484-875-3192
Name
주소
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Name
직원
6
Name
트위터
Name
다음 수익 날짜
2024-12-11
Name
최신 SEC 제출 서류
Name
ANVS's Discussions on Twitter

ANVS을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ANVS
Annovis Bio Inc
2.35 38.58M 0 -40.94M -22.97M -3.84
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-02-10 다운그레이드 D. Boral Capital Buy → Hold
2024-10-25 업그레이드 Maxim Group Hold → Buy
2023-12-29 개시 Canaccord Genuity Buy
2021-07-07 재확인 Maxim Group Buy

Annovis Bio Inc 주식(ANVS)의 최신 뉴스

pulisher
May 28, 2025

INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Securities Class Action Lawsuit Has Been Filed on Behalf of Annovis Bio, Inc. (ANVS) Investors and Encourages Investors to Contact the Firm Before October 18, 2021 - The Globe and Mail

May 28, 2025
pulisher
May 26, 2025

Down Syndrome Market: Epidemiology, Therapies, Companies, - openPR.com

May 26, 2025
pulisher
May 20, 2025

Annovis Bio to Host Patient-Centered Webcast on Key Clinical Developments - MSN

May 20, 2025
pulisher
May 20, 2025

Annovis Bio Advances Phase 3 Alzheimer’s Trial Amid Steady Financial Progress - MSN

May 20, 2025
pulisher
May 17, 2025

Canaccord Genuity Group Issues Pessimistic Forecast for Annovis Bio (NYSE:ANVS) Stock Price - Defense World

May 17, 2025
pulisher
May 16, 2025

Annovis Bio, Inc. (NYSE:ANVS) Given Average Recommendation of “Buy” by Brokerages - Defense World

May 16, 2025
pulisher
May 15, 2025

Annovis Bio (ANVS) Target Price Lowered as Phase 3 Alzheimer's T - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Canaccord cuts Annovis Bio stock target to $17; keeps Buy rating - Investing.com Australia

May 15, 2025
pulisher
May 15, 2025

Levi Strauss To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga

May 15, 2025
pulisher
May 15, 2025

Annovis Bio (ANVS) Price Target Reduced by Canaccord Genuity | ANVS Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Annovis Bio Launches Phase 3 Alzheimer’s Trial, Expands Research Efforts - citybuzz -

May 15, 2025
pulisher
May 13, 2025

Annovis Bio Appoints New Principal Financial Officer - TipRanks

May 13, 2025
pulisher
May 13, 2025

Annovis Provides Corporate Updates And Reports First Quarter 2025 Financial Results - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Annovis Bio Inc. Provides Corporate Updates and Q1 2025 Financial Results, Initiates Pivotal Phase 3 Clinical Trial for Alzheimer’s Disease - Nasdaq

May 13, 2025
pulisher
May 13, 2025

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results - GlobeNewswire

May 13, 2025
pulisher
May 13, 2025

Annovis Bio's New Phase 3 Alzheimer's Drug Trial Targets Both Symptoms and Disease Modification - Stock Titan

May 13, 2025
pulisher
May 10, 2025

Annovis Bio (ANVS) Projected to Post Quarterly Earnings on Monday - Defense World

May 10, 2025
pulisher
May 06, 2025

Annovis Bio Appoints Hui Liu as Director of Biostatistics - MSN

May 06, 2025
pulisher
Apr 30, 2025

Annovis Bio Strengthens Research Team with Appointment of Hui Liu as Director of Biostatistics - citybuzz -

Apr 30, 2025
pulisher
Apr 29, 2025

Annovis Bio hires new director of biostatistics amid AD trial - Investing.com

Apr 29, 2025
pulisher
Apr 29, 2025

Annovis Bio Appoints Hui Liu As Director Of Biostatistics - marketscreener.com

Apr 29, 2025
pulisher
Apr 29, 2025

Annovis Bio Bolsters Alzheimer's Phase 3 Trial Team: Statistics Expert Joins at Critical Stage - Stock Titan

Apr 29, 2025
pulisher
Apr 26, 2025

LAWSUITS FILED AGAINST SLQT, ANVS and VIEWJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 21, 2025

Annovis Bio, Inc. (NYSE:ANVS) Receives Average Recommendation of “Buy” from Analysts - Defense World

Apr 21, 2025
pulisher
Apr 15, 2025

Head-To-Head Survey: Eterna Therapeutics (NASDAQ:ERNA) and Annovis Bio (NYSE:ANVS) - Defense World

Apr 15, 2025
pulisher
Apr 09, 2025

Annovis Bio stock plunges to 52-week low of $1.14 By Investing.com - Investing.com Canada

Apr 09, 2025
pulisher
Apr 09, 2025

Annovis Bio stock plunges to 52-week low of $1.14 - Investing.com

Apr 09, 2025
pulisher
Apr 09, 2025

Buntanetap shows early potential for Parkinson’s-related dementia - The Pharma Letter

Apr 09, 2025
pulisher
Apr 08, 2025

Parkinson's Disease Pipeline Analysis and Clinical Trials - openPR.com

Apr 08, 2025
pulisher
Apr 03, 2025

Buntanetap for Parkinson’s disease - Parkinson's News Today

Apr 03, 2025
pulisher
Apr 02, 2025

Annovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development Summit - MSN

Apr 02, 2025
pulisher
Mar 31, 2025

Annovis Bio stock hits 52-week low at $1.52 amid sharp decline By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Annovis Bio stock hits 52-week low at $1.52 amid sharp decline - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

Annovis Bio Receives Non-Compliance Notice from NYSE - MSN

Mar 31, 2025
pulisher
Mar 30, 2025

Annovis Bio to Present Promising Data on Buntanetap at AD/PD™ 2025 - MSN

Mar 30, 2025
pulisher
Mar 27, 2025

Annovis Bio faces NYSE delisting over market cap, equity shortfall By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Annovis Bio Gets NYSE Noncompliance Notice - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Annovis Bio Faces NYSE Non-Compliance Notice - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Annovis Bio faces NYSE delisting over market cap, equity shortfall - Investing.com

Mar 27, 2025

Annovis Bio Inc (ANVS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
자본화:     |  볼륨(24시간):